Lascufloxacin hydrochloride to treat bacterial infection.

Abstract

Lascufloxacin hydrochloride (AM-1977) is a novel 8-methoxy fluoroquinolone antibacterial agent with a unique pharmacophore at the 1st and 7th positions of the quinoline nucleus developed by Kyorin Pharmaceutical Co., Ltd. (Tokyo, Japan). It has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for treatment of respiratory tract and ear, nose and throat infections including community-acquired pneumonia and otorhinolaryngological infections, and shows great promise against fluoroquinolone-resistant strains of major pathogens which infect the respiratory tract. It is suitable for treating infections caused by Staphylococcus, Streptococcus, Pneumococcus, Moraxella (Branhamella) catarrhalis, Klebsiella, Enterobacter, Haemophilus influenzae, Legionella pneumophila, Prevotella and Mycoplasma pneumoniae that are sensitive to this drug.

• Authors: R Thakare, S Singh, A Dasgupta, S Chopra
• Journal: Drugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 56 Issue 6 Pg. 365-376 (Jun 2020) ISSN: 1699-3993 [Print] Spain
• PMID: 32525135 (Publication Type: Journal Article)
• Copyright: Copyright 2020 Clarivate Analytics.

Chemical References

• Anti-Bacterial Agents
• Fluoroquinolones
• lascufloxacin

Topics

• Anti-Bacterial Agents (therapeutic use)
• Bacterial Infections (drug therapy)
• Drug Resistance, Bacterial
• Fluoroquinolones (therapeutic use)
• Humans
• Japan